Latest Headlines
-
Invenra Inc. Announces A Strategic Research Agreement With Astellas Pharma In Therapeutic Bispecific Antibody Discovery
4/9/2024
Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients.
-
Stealth Biotherapeutics Announces FDA Acceptance Of New Drug Application For Elamipretide For The Treatment Of Barth Syndrome
4/8/2024
Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration ("FDA") has accepted for filing its New Drug Application ("NDA") for elamipretide for the treatment of Barth syndrome.
-
Shorla Oncology Announces FDA Filing Acceptance Of New Drug Application To Treat Certain Forms Of Leukemia And Other Cancers
4/8/2024
Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for SH-201, the first palatable oral liquid of the related chemotherapeutic agent to treat certain forms of leukemia and other cancers.
-
A Simple, Inexpensive Way To Make Carbon Atoms Bind Together
4/5/2024
The active ingredient in many drugs is what’s known as a small molecule: bigger than water, much smaller than an antibody and mainly made of carbon.
-
New Method Unveils Secrets Of Protein Interactions With Potential For Drug Discovery
4/4/2024
Scientists from the University of Oulu and Texas A&M University have developed a new method to study how proteins interact with small ligand molecules, paving the way, for example, for faster and more efficient drug discovery.
-
Aurigene Pharmaceutical Services Ltd. Introduces Aurigene.AI, An Artificial Intelligence (AI) And Machine Learning (ML) Assisted Drug Discovery Platform
4/3/2024
Aurigene Pharmaceutical Services Limited (Aurigene), a contract research, development, and manufacturing services organization and a Dr. Reddy’s Laboratories company, introduces Aurigene.AI, an AI and ML-assisted platform for accelerating drug discovery projects from hit identification to candidate nomination.
-
Convergent Therapeutics Announces FDA Clearance Of IND Application For CONV01-α, A Best-In-Class Radioantibody Targeting Prostate-Specific Membrane Antigen
4/2/2024
Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for the treatment of prostate cancer and other cancers, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the investigational new drug ("IND") application for CONV01-α, its lead candidate for the treatment of patients with advanced prostate cancer.
-
Infinant Health Announces Submission Of Orphan Drug Designation Application
4/2/2024
Infinant Health, a privately-held company focused on changing the trajectory of human health, one baby at a time, announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its drug candidate INF108 for the prevention of necrotizing enterocolitis in pre-term infants.
-
Mosaic Biosciences Expands Its Leading Drug Discovery And Development Expertise
4/2/2024
Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery. Both recognized leaders join the company as it grows to meet increased demand for its comprehensive and integrated drug discovery research services.
-
New Antibiotic Class Effective Against Multidrug-Resistant Bacteria
4/1/2024
Scientists at Uppsala University have discovered a new class of antibiotics with potent activity against multi-drug resistant bacteria, and have shown that it cures bloodstream infections in mice. The new antibiotic class is described in an article in the scientific journal PNAS.